philipn authored on Nov. 15, 2020, 5:34 p.m. | | Additions are marked like this |
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which is being trialed for possible therapeutic use in COVID-19. In an abstract published in October, 2020, fluvoxamine showed promise in a randomized, placebo-controlled trial of 152 COVID-19 positive outpatients: 152 participants were randomized in the modified intention to treat group. No patients (0/80, 0%) in the fluvoxamine group clinically deteriorated, compared to 8.3% (6/72) in the placebo group (logrank chi-square 6.8, p=0.009). Fluoxetine has also shown anti-SARS-CoV-2 activity in vitro in Vero and Calu-3 cells. Mechanism of possible benefit?Sigma-1 receptorMechanisms of potential benefit in COVID-19 may include sigma-1 receptor agonism. See "Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor" and "Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis". As SSRIAn observational study of 7,345 hospitalized COVID-19 patients hinted at possible benefit of prior SSRI usage. As an anti-viralIn an October, 2020 preprint, fluoxetine showed in vitro anti-SARS-CoV-2 activity in Vero and Calu-3 cells. See also |
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which is being trialed for possible therapeutic use in COVID-19. Fluvoxamine showed promise in a randomized, placebo-controlled trial of 152 COVID-19 positive outpatients. In a paper published in November, 2020 in the Journal of the American Medical Association: Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009). The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events. -JAMA Fluoxetine has also shown anti-SARS-CoV-2 activity in vitro in Vero and Calu-3 cells. Mechanism of possible benefit?Sigma-1 receptorMechanisms of potential benefit in COVID-19 may include sigma-1 receptor agonism. See "Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor" and "Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis". As SSRIAn observational study of 7,345 hospitalized COVID-19 patients hinted at possible benefit of prior SSRI usage. As an anti-viralIn an October, 2020 preprint, fluoxetine showed in vitro anti-SARS-CoV-2 activity in Vero and Calu-3 cells. See also |
